Literature DB >> 16189117

Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus.

Noe Reyes1, Robert Skinner, Koné Kaniga, Kevin M Krause, Josephine Shelton, Glenmar P Obedencio, Alexander Gough, Michael Conner, Sharath S Hegde.   

Abstract

The efficacy of telavancin, a bactericidal lipoglycopeptide, was compared to that of vancomycin and linezolid against methicillin-resistant Staphylococcus aureus (MRSA) in a murine pneumonia model. Telavancin produced greater reductions in lung bacterial titer and mortality than did vancomycin and linezolid at human doses equivalent to those described by the area under the concentration-time curve. These results suggest the potential utility of telavancin for treatment of MRSA pneumonia.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16189117      PMCID： PMC1251517          DOI： 10.1128/AAC.49.10.4344-4346.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects.

Authors:  J P Shaw; J Seroogy; K Kaniga; D L Higgins; M Kitt; S Barriere
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.

Authors:  Deborah L Higgins; Ray Chang; Dmitri V Debabov; Joey Leung; Terry Wu; Kevin M Krause; Erik Sandvik; Jeffrey M Hubbard; Koné Kaniga; Donald E Schmidt; Qiufeng Gao; Robert T Cass; Dane E Karr; Bret M Benton; Patrick P Humphrey
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

3.  Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog.

Authors:  J G Slatter; L A Adams; E C Bush; K Chiba; P T Daley-Yates; K L Feenstra; S Koike; N Ozawa; G W Peng; J P Sams; M R Schuette; S Yamazaki
Journal:  Xenobiotica       Date:  2002-10       Impact factor: 1.908

4.  Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers.

Authors:  D P Healy; R E Polk; M L Garson; D T Rock; T J Comstock
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

5.  Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers.

Authors:  Dennis J Stalker; Gail L Jungbluth; Nancy K Hopkins; Donald H Batts
Journal:  J Antimicrob Chemother       Date:  2003-03-28       Impact factor: 5.790

6.  Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.

Authors:  E Rubinstein; S Cammarata; T Oliphant; R Wunderink
Journal:  Clin Infect Dis       Date:  2001-01-26       Impact factor: 9.079

7.  Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.

Authors:  Sharath S Hegde; Noe Reyes; Tania Wiens; Nicole Vanasse; Robert Skinner; Julia McCullough; Koné Kaniga; John Pace; Roger Thomas; Jeng-Pyng Shaw; Glen Obedencio; J Kevin Judice
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

8.  In vitro activity of TD-6424 against Staphylococcus aureus.

Authors:  John L Pace; Kevin Krause; Deborah Johnston; Dmitri Debabov; Terry Wu; Lesley Farrington; Cassie Lane; Deborah L Higgins; Burt Christensen; J Kevin Judice; Koné Kaniga
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

Review 9.  Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid.

Authors:  William A Craig
Journal:  Infect Dis Clin North Am       Date:  2003-09       Impact factor: 5.982

10.  The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee.

Authors:  J L Vincent; D J Bihari; P M Suter; H A Bruining; J White; M H Nicolas-Chanoin; M Wolff; R C Spencer; M Hemmer
Journal:  JAMA       Date:  1995 Aug 23-30       Impact factor: 56.272
View more
  24 in total

1.  Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.

Authors:  Alasdair P MacGowan; Alan R Noel; Sharon Tomaselli; Heather C Elliott; Karen E Bowker
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

Review 2.  Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Authors:  Biswadeep Das; Chayna Sarkar; Debasmita Das; Amit Gupta; Arnav Kalra; Shubham Sahni
Journal:  Ther Adv Infect Dis       Date:  2017-03-08

3.  Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model.

Authors:  Inga Odenholt; Elisabeth Löwdin; Otto Cars
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

4.  PEGylated liposome encapsulation increases the lung tissue concentration of vancomycin.

Authors:  Krishna Muppidi; Jeffrey Wang; Guru Betageri; Andrew S Pumerantz
Journal:  Antimicrob Agents Chemother       Date:  2011-07-25       Impact factor: 5.191

5.  Successful target attainment of telavancin at elevated MICs: fact or fiction?

Authors:  Andras Farkas
Journal:  Antimicrob Agents Chemother       Date:  2012-08       Impact factor: 5.191

6.  Daptomycin and tigecycline have broader effective dose ranges than vancomycin as prophylaxis against a Staphylococcus aureus surgical implant infection in mice.

Authors:  Jared A Niska; Jonathan H Shahbazian; Romela Irene Ramos; Jonathan R Pribaz; Fabrizio Billi; Kevin P Francis; Lloyd S Miller
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

7.  Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.

Authors:  José M Miró; Cristina García-de-la-Mària; Yolanda Armero; Elisa de-Lazzari; Dolors Soy; Asunción Moreno; Ana del Rio; Manel Almela; Carlos A Mestres; José M Gatell; María-Teresa Jiménez-de-Anta; Francesc Marco
Journal:  Antimicrob Agents Chemother       Date:  2007-05-07       Impact factor: 5.191

Review 8.  Telavancin: a review of its use in patients with nosocomial pneumonia.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

9.  Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.

Authors:  Mark H Gotfried; Jeng-Pyng Shaw; Bret M Benton; Kevin M Krause; Michael R Goldberg; Michael M Kitt; Steven L Barriere
Journal:  Antimicrob Agents Chemother       Date:  2007-10-08       Impact factor: 5.191

10.  In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains.

Authors:  Kerry L LaPlante; Leonard A Mermel
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.